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Microvascular endothelial dysfunction predicts the
development of erectile dysfunction in men with coronary
atherosclerosis without critical stenoses
Martin Reriania, Andreas J. Flammera, Jing Lia, Megha Prasada, Charanjit Rihala,
Abhiram Prasada, Ryan Lennonc, Lilach O. Lermanb and Amir Lermana
Background Erectile dysfunction (ED) is associated with
an increased risk for cardiovascular disease, stroke, and all-
cause mortality, independent of conventional cardiovascular
risk factors. Coronary endothelial dysfunction is
independently associated with ED in men with early
coronary atherosclerosis. We aimed to investigate whether
coronary microvascular dysfunction predicts development
of ED in patients presenting with coronary atherosclerosis
without critical stenoses.
Patients and methods Coronary microvascular function
was evaluated in 130 men with coronary atherosclerosis
without critical stenoses by administration of intracoronary
acetylcholine at the time of diagnostic study. After a mean
follow-up of 8.4 years, patients were assessed for the
development of ED by administration of a questionnaire.
Results In all, 68 (50%) men had microvascular endothelial
dysfunction at baseline; 35 (51%) men with microvascular
endothelial dysfunction developed ED on follow-up
compared with 19 (31%) men without microvascular
endothelial dysfunction. Men who developed ED had a lower
coronary blood flow response (% ΔCBF) compared with
men who did not develop ED, with mean±SD of 25.4 ± 71.3
versus 81.7± 120 (P= 0.003). In univariate analysis,
microvascular endothelial dysfunction was a predictor for
the development of ED, with relative risk of 2.4 (1.2–4.9)
(P= 0.016). In multivariate logistic regression adjusting for
traditional cardiovascular risk factors (age, hypertension,
hyperlipidemia, diabetes, vascular disease, and family
history of coronary artery disease), only microvascular
endothelial dysfunction (P= 0.027) and age (P= 0.044)
remained significant predictors of development of ED.
Conclusion Coronary microvascular dysfunction is a
predictor of the development of ED in men with coronary
atherosclerosis without critical stenoses. This study
underscores the systemic involvement of the endothelial
function in vascular disease. Coron Artery Dis 25:552–557
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Introduction
Erectile dysfunction (ED) has a high prevalence world-
wide, affecting 40% of men above 40 years of age [1] with
considerable impact on the quality of life of middle-aged
and elderly men. It is estimated that there are over 150
million men with ED worldwide and the number is
projected to increase to 320 million by the year 2025 [2].
ED was formerly thought of as a psychological condition,
but it is now known to be predominantly a vascular dis-
ease of penile circulation [3]. It shares many of the risk
factors of cardiovascular disease (CVD) [4,5] and is itself
an independent marker of increased risk for CVD, cor-
onary heart disease, stroke, and all-cause mortality [6,7].
Indeed, ED is thought to precede cardiovascular (CV)
events by 3–5 years [8–10], and its early identification
provides an opportunity for CV risk reduction [11].
Endothelial dysfunction is the initial stage of the athero-
sclerotic process involving multiple vascular beds, including
the penile [12,13] and coronary circulation [14]. Previous
studies have shown increased risk for future CV events in
patients with both coronary and systemic endothelial dys-
function [15–18]. Markers of endothelial dysfunction are
increased in patients with ED compared with controls [19,
20]. We have also recently shown that coronary endothelial
dysfunction is independently associated with ED in men
with early coronary atherosclerosis [21].
However, the temporal relationship between endothelial
dysfunction and risk of developing ED is not known.
Therefore, this study tested the hypothesis that coronary
epicardial and microvascular endothelial function pre-
cede and predict the development of ED in middle-
aged men.
Patients and methods
Study design
This study was a prospective single-center cohort study.
The Mayo Clinic Institutional Review Board approved
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the study and informed consent was obtained from all
patients.
Study population
The study group consisted of 130 men with coronary
atherosclerosis without critical stenoses and free from ED
at baseline, who were referred to the cardiac catheteriza-
tion laboratory for evaluation of coronary artery disease,
were found to have nonobstructive disease, and had a
comprehensive coronary physiology study, including the
assessment of endothelial function and nonendothelium-
independent coronary flow reserve (CFR) [22–25].
Exclusion criteria included significant coronary artery
stenosis (>40%), ejection fraction less than 45%, unstable
angina, previous myocardial infarction, use of radio-
graphic contrast agents within 12 h, and significant sys-
temic disease. Medications that may affect CV
hemodynamics were discontinued for at least 48 h before
the study.
Study protocol
At baseline, diagnostic coronary angiography and deter-
mination of endothelium-dependent changes in coronary
blood flow (CBF) and endothelium-independent CFR
were performed as previously described [24,26,27]. A
Doppler guide wire (0.014 inch diameter, FloWire;
Volcano Corporation, San Diego, California, USA) within
a 2.2 F coronary infusion catheter (Ultrafuse; SciMed
Life System, Maple Grove, Minnesota, USA) was
advanced and positioned in the middle portion of the left
anterior descending coronary artery (LAD). Intracoronary
bolus injections of incremental doses (18–36 μg) of ade-
nosine (Fujisawa, Kanagawa Prefecture, Japan), an
endothelium-independent vasodilator (primarily of the
microcirculation) [28], were administered into the guid-
ing catheter until maximal hyperemia was achieved.
Assessment of the endothelium-dependent changes in
CBF was performed by selective infusion of acetylcholine
(ACh) into the LAD. ACh (Iolab Pharmaceuticals,
Peterborough, Ontario, Canada), 10–6, 10–5, and 10–4 mol/l,
was infused at 1ml/min for 3min [26,29]. Hemodynamic
data (heart rate and mean arterial pressure), Doppler
measurements, and coronary angiography were obtained
after each infusion. Endothelium-independent epicardial
vasodilation was assessed with an intracoronary bolus
injection of nitroglycerin (200 μg; Abbott Laboratories,
Abbott Park, Illinois, USA) [30].
Quantitative coronary angiography
Coronary artery diameter was analyzed by quantitative
coronary angiography from digital images with modification
of a previously described technique from our institution [24,
26,27]. The LAD was divided into proximal, middle, and
distal segments. For each segment, the measurements were
performed in the region showing the greatest change during
the ACh infusion. An angiographically smooth segment of
the proximal, middle, and distal LAD, free of any over-
lapping branch vessels, was identified in each patient and
served as the reference diameter for calculation of diameter
stenosis. End-diastolic cine frames that best showed the
segment were selected, and calibration of the video and
cine images was performed, identifying the diameter of the
guide catheter. Quantitative measurements of the coronary
arteries were obtained using a computer-based image ana-
lysis system. Segment diameters were determined at
baseline and after both ACh and nitroglycerin administra-
tion. The proximal segment, which was not exposed to
ACh, served a control segment.
Assessment of coronary blood flow
Doppler flow velocity spectra were analyzed online to
determine the time-averaged peak velocity. Volumetric
CBF was determined from the following relation:
CBF= cross-sectional area× average peak velocity× 0.5
[31]. Endothelium-dependent microvascular function
was calculated as % ΔCBF in response to ACh as pre-
viously described [32].
Microvascular endothelial dysfunction
As in previous studies, microvascular endothelial dys-
function was defined as 50% or less increase in CBF in
response to the maximal dose of ACh compared with
baseline CBF [21,22,33].
Follow-up
Long-term follow-up was performed by a questionnaire
asking the patients about the development of ED since
their coronary vascular study. The questionnaire asked
about any incident ED (new diagnosis) that developed
after the comprehensive coronary vascular reactivity
study.
Statistical analysis
Data are displayed as mean ± SD or counts and percen-
tages as appropriate. Variables with heavily skewed dis-
tribution are reported as the median with first and third
quartiles in parenthesis. Comparison of demographic and
baseline clinical data between the groups was performed
using Student’s t-test for continuous data and Pearson’s
χ2-test for categorical data.
Results
We studied 130 men, of whom 68 (52%) had micro-
vascular endothelial dysfunction at baseline. The mean
age at baseline was 50 ± 11 years. History of hypertension
was present in 44%, hyperlipidemia in 64%, diabetes in
10%, and family history of coronary artery disease in 60%
of patients enrolled. The mean duration of follow-up was
8.4 ± 4.7 years.
Microvascular endothelial function and ED Reriani et al. 553
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Coronary microvascular function and erectile
dysfunction
The study population was divided into two groups: those
with microvascular endothelial dysfunction (% ΔCBF to
ACh≤ 50%, n= 68) and those with normal microvascular
endothelial function (% ΔCBF to ACh> 50%, n= 62).
Baseline characteristics
The baseline characteristics and use of CV medications at
the time of functional angiogram were similar between
the two groups except for family history of coronary
artery disease and smoking history. Patients with micro-
vascular endothelial dysfunction had a higher incidence
of ED at follow-up compared with patients with
normal endothelial function, 50 versus 30% (P= 0.016)
(Table 1).
During the follow-up period, 54 (40%) patients devel-
oped ED. Patients who developed ED were older
(54 ± 9.7 vs. 47 ± 11.7 years, P= 0.0011) and had a higher
prevalence of diabetes (20 vs. 4%, P= 0.0017) compared
with those who did not develop ED. ΔCBF and CFR
were lower in patients who developed ED compared
with those who did not (Table 2 and Figs 1 and 2), but
there was no difference in the percentage change in
coronary artery diameter (% ΔCAD) (Fig. 3).
Univariate and adjusted models
Univariate analysis identified the presence of micro-
vascular endothelial dysfunction [odds ratio (OR) 2.4,
95% confidence interval (CI) 1.18–4.99, P= 0.016],
diabetes (OR 6.74, 95% CI 1.98–31, P= 0.0017), high-
sensitive C-reactive protein (P= 0.0047), and increasing
age (OR 1.6 for 10-year increase, 95% CI 1.2–2.5, P= 0.0
19) as significant predictors for development of ED
(Table 3).
In multivariate analysis adjusting for traditional CV risk
factors (age, BMI, hypertension, diabetes, hyperlipide-
mia, family history of coronary artery disease, and
smoking), only microvascular endothelial dysfunction
(OR 2.67, 95% CI 1.13–6.6, P= 0.024) and age
(P= 0.0458) were independent predictors of develop-
ment of ED.
Table 1 Baseline patient characteristics
Normal
endothelial
function (n=62)
Microvascular
dysfunction
(n=68) P
Age (years) 49 ±12.4 51 ±10.5 0.27
BMI (kg/m2) 27.7 ±4.6 29.1 ±5.6 0.12
Hypertension 25 (40) 33 (49) 0.33
Diabetes 4 (6) 10 (14) 0.12
Hypercholesterolemia 42 (68) 44 (66) 0.71
Family history coronary
artery disease
28 (47) 48 (75) 0.0012
Smoking
Former 25 (40) 31 (46) 0.0308
Current 12 (19) 3 (4)
Testosterone 399 ±187 418 ± 139 0.81
C-reactive protein 1.69 ±3.4 1.34 ±1.90 0.55
Aspirin 33 (53) 45 (66) 0.13
ACE inhibitor 13 (21) 13 (19) 0.79
β-Blockers 17 (27) 23 (34) 0.43
Ca2+ channel blocker 19 (31) 30 (44) 0.13
Lipid lowering 25 (40) 35 (51) 0.20
Oral hypoglycemic 3 (5) 7 (10) 0.93
Diuretics 5 (8) 6 (9) 0.88
% ΔCBF 135.8 ± 102 −12.3 ±40.3 –
% ΔCAD 28.2 ± 22.7 −7.6 ±16.1 <0.001
CFR 3.3 ±0.83 3.0 ± 0.72 0.049
Values are expressed as mean ±SD or n (%).
ACE, angiotensin-converting-enzyme; % ΔCAD, percent change in coronary
artery diameter to acetylcholine; % ΔCBF, percent change in coronary blood flow
to acetylcholine; CFR, coronary flow reserve.
Table 2 Patient characteristics by erectile dysfunction
No ED (n=76) ED (n=54) P
Age (years) 47.7 ±12 54 ±9.7 0.002
BMI (kg/m2) 27.8 ±5.6 29.5 ±4.4 0.06
Hypertension 31 (41) 27 (50) 0.33
Diabetes 3 (4) 11 (20) 0.0029
Hypercholesterolemia 46 (61) 40 (74) 0.11
Family history coronary artery
disease
46 (63) 30 (58) 0.64
Smoking
Former 11 (15) 4 (8) 0.16
Current 28 (37) 28 (52)
Testosterone 437 ±163 395 ±149 0.59
C-reactive protein 2.16 ±3.36 0.7 ± 1.12 0.013
Aspirin 42 (55) 47 (87) 0.19
ACE inhibitor 10 (13) 19 (35) 0.021
β-Blockers 21 (28) 21 (39) 0.36
Ca2+ channel blocker 28 (37) 26 (48) 0.86
Statins 30 (39) 29 (54) 0.07
Diuretics 7 (9) 4 (7) 0.71
% ΔCBF 81.7 ±120 25.4 ±71.3 0.0026
% ΔCAD −15.4 ±22.0 −22.7 ± 22.1 0.065
CFR 3.3 ±0.88 3.0 ± 0.75 0.068
Values are expressed as mean ±SD or n (%).
ACE, angiotensin-converting-enzyme; % ΔCAD, percent change in coronary
artery diameter to acetylcholine; % ΔCBF, percent change in coronary blood flow
to acetylcholine; CFR, coronary flow reserve; ED, erectile dysfunction.
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Coronary flow reserve and coronary epicardial function
In univariate analysis, CFR (P=0.0374) was a predictor of
development of ED, but this was not so in multivariate
analysis adjusting for traditional risk factors. % ΔCAD
was not a predictor of development of ED in univariate
analysis.
Discussion
The present study demonstrates that the presence of
coronary microvascular endothelial dysfunction is an
independent marker of ED in middle-aged men without
coronary artery disease. Of the traditional risk factors for
atherosclerosis, only diabetes and age were predictive of
the development of ED in univariate analysis. In multi-
variate analysis, however, only microvascular endothelial
dysfunction and increasing age predicted the develop-
ment of ED. Thus, the current study supports an
important role for microcirculatory dysfunction as a
potential mechanism and marker for ED.
Endothelial dysfunction is associated with most CV risk
factors and is considered a key event in the initiation,
progression, and complications of atherosclerosis [34,35].
Indeed, the effect of age and diabetes on development of
ED observed in this study may be mediated by the
microcirculation [36]. ED shares many of the modifiable
risk factors with CVD. Both endothelial dysfunction and
ED have also been shown to be independent markers of
increased risk for CVD [6,7,17].
Several studies have shown an association between
endothelial function (both in coronary and systemic cir-
culation), ED, and CVD [16,19,20]. We have previously
shown that endothelial function, measured peripherally
using peripheral artery tonometry, predicts adverse
events in the coronary circulation [37] and endothelial
dysfunction in the coronary bed predicts the develop-
ment of strokes [18]. We have also demonstrated that
coronary microvascular disease is associated with abnor-
mal glomerular filtration rate [38]. In this study, we fur-
ther extended this link by showing that coronary
microvascular endothelial dysfunction is an independent
marker for increased risk of developing ED in middle-
aged men with higher predictive value than conventional
CV risk factors.
Endothelial dysfunction represents an integrated index
of both the overall traditional and novel CV risk factor
burden and the sum of all vasculoprotective factors in an
individual [35,39]. Endothelial dysfunction is a systemic
disorder affecting vascular beds in different regions, and
its detection in one vascular bed could phenotypically
manifest itself as a clinical abnormality in a different
vascular region.
Penile erection occurs in response to sexual stimulation
and the subsequent release of nitric oxide from auto-
nomic nerves and endothelial cells in the corpus caver-
nosum. Microvascular dysfunction within the pelvic
organs would have a negative effect on the perfusion and
oxygenation of these organs and their autonomic nerves.
Traditional risk factors are associated with ED and cause
endothelial dysfunction in the penile vascular system.
Endothelial dysfunction and hypoxia within the corpus
cavernosum are known to be important in the patho-
physiology of ED [40].
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Table 3 Univariate analysis of risk factors for erectile dysfunction
Variables Odds ratio (95% CI)
Age, per 10-year increase 1.6 (1.2–2.5)
Hyperlipidemia 2.02 (0.96–4.38)
Diabetes 6.74 (1.98–31)
Hypertension 2.02 (0.96–4.38)
Family history of coronary artery disease 1.08 (0.53–2.22)
Microvascular dysfunction 2.4 (1.18–4.99)
CI, confidence interval.
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ED is an independent risk factor for CVD, and its diag-
nosis precedes cardiac events by about 3–5 years [8–10].
The recent consensus conference on the management of
ED and CVD recommended CV risk assessments in men
with ED and lifestyle changes to reduce CV risk and
improve erectile function [41]. A recent study also
demonstrated that treatment with phosphodiesterase
inhibitor improved endothelial function in patients with
diabetes [42], underscoring the link between ED and
endothelial function.
In this study, we have shown that endothelial dysfunc-
tion is predictive of the development of ED. Hence, the
discovery of endothelial dysfunction in any vascular bed
should be taken into consideration and appropriate
management of CV risk factors instituted. The increased
risk of developing ED in men with endothelial dys-
function could serve as an added impetus for the less
motivated men to undertake lifestyle modification for CV
risk reduction. In addition, the use of phosphodiesterase
inhibitors for management of ED may also improve sys-
temic endothelial function [42]; however, more studies
are needed to determine whether this therapy positively
impacts CVD.
Study limitations
There are several limitations to be mentioned. First,
development of ED was determined by questionnaires
that were filled by the patients, and thus may be
underestimated. Patients self-reported a new diagnosis of
ED that occurred after the coronary endothelial function
testing. We did not use a validated questionnaire to
assess ED in the cohort. We were thus limited in ver-
ifying the diagnosis of ED. There is also the risk for recall
bias from patients who were diagnosed with ED or were
embarrassed to report such a diagnosis.
Second, we considered all diagnoses of ED and did not
differentiate between vasculogenic ED and ED from
other causes. We would speculate that the association is
the strongest for vasculogenic ED, and performance of
penile Doppler ultrasound studies would have made the
study stronger.
Third, our study was not designed to measure whether
improvement in endothelial function had an impact on
the diagnosis of ED. Patients diagnosed with endothelial
dysfunction were provided with treatment, and this may
have led to improved endothelial function and led to
regression to the mean of our results.
Conclusion
We demonstrated that coronary microvascular endothelial
dysfunction is a marker of increased risk of developing
ED in middle-aged men without coronary artery disease
independent of traditional CV risk factors. The current
study further supports the role of the microcirculation as
a mechanism and potential therapeutic target in CVD.
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